📖

Donanemab TRAILBLAZER Open-Label Extension

active

wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-donanemab-trailblaz

Related Entities

clinical-trials-donanemab-trailblazer-open-label

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Linked Artifacts (20)

related🧫Macroautophagy Dysfunction in PD - Experiment Design70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Macroautophagy Dysfunction in PD - Experiment Design70%

related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides63%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

related🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

mentions🧪Ocular Immune Privilege Extension50%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧪APOE Isoform Conversion Therapy50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

related🧪Ocular Immune Privilege Extension40%

mentions🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%

💬 Discussion